These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 30080722)

  • 1. Circulating Free Methylated Tumor DNA Markers for Sensitive Assessment of Tumor Burden and Early Response Monitoring in Patients Receiving Systemic Chemotherapy for Colorectal Cancer Liver Metastasis.
    Bhangu JS; Beer A; Mittlböck M; Tamandl D; Pulverer W; Schönthaler S; Taghizadeh H; Stremitzer S; Kaczirek K; Gruenberger T; Gnant M; Bergmann M; Mannhalter C; Weinhäusel A; Oehler R; Bachleitner-Hofmann T
    Ann Surg; 2018 Nov; 268(5):894-902. PubMed ID: 30080722
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic influence of hepatic margin after resection of colorectal liver metastasis: role of modern preoperative chemotherapy.
    Makowiec F; Bronsert P; Klock A; Hopt UT; Neeff HP
    Int J Colorectal Dis; 2018 Jan; 33(1):71-78. PubMed ID: 29098384
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Postoperative serum methylation levels of TAC1 and SEPT9 are independent predictors of recurrence and survival of patients with colorectal cancer.
    Tham C; Chew M; Soong R; Lim J; Ang M; Tang C; Zhao Y; Ong SY; Liu Y
    Cancer; 2014 Oct; 120(20):3131-41. PubMed ID: 24925595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined detection of plasma GATA5 and SFRP2 methylation is a valid noninvasive biomarker for colorectal cancer and adenomas.
    Zhang X; Song YF; Lu HN; Wang DP; Zhang XS; Huang SL; Sun BL; Huang ZG
    World J Gastroenterol; 2015 Mar; 21(9):2629-37. PubMed ID: 25759530
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CEA change after neoadjuvant chemotherapy including bevacizumab and clinical outcome in patients undergoing liver resection for colorectal liver metastases.
    Stremitzer S; Stift J; Graf A; Singh J; Starlinger P; Gruenberger B; Tamandl D; Gruenberger T
    Ann Surg Oncol; 2015 Apr; 22(4):1315-23. PubMed ID: 25323471
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating cell-free DNA in plasma of colorectal cancer patients - A potential biomarker for tumor burden.
    Bhangu JS; Taghizadeh H; Braunschmid T; Bachleitner-Hofmann T; Mannhalter C
    Surg Oncol; 2017 Dec; 26(4):395-401. PubMed ID: 29113658
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved tumour marker sensitivity in detecting colorectal liver metastases by combined type IV collagen and CEA measurement.
    Nyström H; Tavelin B; Björklund M; Naredi P; Sund M
    Tumour Biol; 2015 Dec; 36(12):9839-47. PubMed ID: 26162539
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential of quantitative SEPT9 and SHOX2 methylation in plasmatic circulating cell-free DNA as auxiliary staging parameter in colorectal cancer: a prospective observational cohort study.
    Bergheim J; Semaan A; Gevensleben H; Groening S; Knoblich A; Dietrich J; Weber J; Kalff JC; Bootz F; Kristiansen G; Dietrich D
    Br J Cancer; 2018 May; 118(9):1217-1228. PubMed ID: 29610456
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cell-Free Circulating Methylated SEPT9 for Noninvasive Diagnosis and Monitoring of Colorectal Cancer.
    Fu B; Yan P; Zhang S; Lu Y; Pan L; Tang W; Chen S; Chen S; Zhang A; Liu W
    Dis Markers; 2018; 2018():6437104. PubMed ID: 29849824
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma Dynamics of RAS/RAF Mutations in Patients With Metastatic Colorectal Cancer Receiving Chemotherapy and Anti-EGFR Treatment.
    Thomsen CB; Andersen RF; Lindebjerg J; Hansen TF; Jensen LH; Jakobsen A
    Clin Colorectal Cancer; 2019 Mar; 18(1):28-33.e3. PubMed ID: 30459076
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methylated free-circulating HPP1 DNA is an early response marker in patients with metastatic colorectal cancer.
    Herbst A; Vdovin N; Gacesa S; Ofner A; Philipp A; Nagel D; Holdt LM; Op den Winkel M; Heinemann V; Stieber P; Graeven U; Reinacher-Schick A; Arnold D; Ricard I; Mansmann U; Hegewisch-Becker S; Kolligs FT
    Int J Cancer; 2017 May; 140(9):2134-2144. PubMed ID: 28124380
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circadian Rhythm of Methylated Septin 9, Cell-Free DNA Amount and Tumor Markers in Colorectal Cancer Patients.
    Tóth K; Patai ÁV; Kalmár A; Barták BK; Nagy ZB; Galamb O; Wichmann B; Tulassay Z; Molnár B
    Pathol Oncol Res; 2017 Jul; 23(3):699-706. PubMed ID: 28035516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Host MICA Polymorphism as a Potential Predictive Marker in Response to Chemotherapy for Colorectal Liver Metastases.
    Nishioka Y; Shindoh J; Inagaki Y; Gonoi W; Mitsui J; Abe H; Yoshioka R; Yoshida S; Fukayama M; Tsuji S; Hashimoto M; Hasegawa K; Kokudo N
    Dig Dis; 2018; 36(6):437-445. PubMed ID: 29969766
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Type IV collagen as a tumour marker for colorectal liver metastases.
    Nyström H; Naredi P; Hafström L; Sund M
    Eur J Surg Oncol; 2011 Jul; 37(7):611-7. PubMed ID: 21620632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Roles of Methylated DNA Biomarkers in Patients with Colorectal Cancer.
    Ma Z; Williams M; Cheng YY; Leung WK
    Dis Markers; 2019; 2019():2673543. PubMed ID: 30944663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epigenome-wide discovery and evaluation of leukocyte DNA methylation markers for the detection of colorectal cancer in a screening setting.
    Heiss JA; Brenner H
    Clin Epigenetics; 2017; 9():24. PubMed ID: 28270869
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recurrence risk assessment for stage III colorectal cancer based on five methylation biomarkers in plasma cell-free DNA.
    Wang W; Zhu X; Zhang X; Lei C; Zeng Z; Lan X; Cui W; Wang F; Xu S; Zhou J; Wu X; Deng H; Li X; Fan J; Ding Y; Huang Z; Liang L
    J Pathol; 2023 Apr; 259(4):376-387. PubMed ID: 36573552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liver resection for gastric cancer metastases.
    Viganò L; Vellone M; Ferrero A; Giuliante F; Nuzzo G; Capussotti L
    Hepatogastroenterology; 2013 May; 60(123):557-62. PubMed ID: 23635434
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concordance of Carcinoembryonic Antigen Ratio and Response Evaluation Criteria in Solid Tumors as Prognostic Surrogate Indicators of Metastatic Colorectal Cancer Patients Treated with Chemotherapy.
    Huang SC; Lin JK; Lin TC; Chen WS; Yang SH; Wang HS; Lan YT; Lin CC; Jiang JK; Chang SC
    Ann Surg Oncol; 2015 Jul; 22(7):2262-8. PubMed ID: 25586242
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Response to neoadjuvant chemotherapy does not predict overall survival for patients with synchronous colorectal hepatic metastases.
    Gallagher DJ; Zheng J; Capanu M; Haviland D; Paty P; Dematteo RP; D'Angelica M; Fong Y; Jarnagin WR; Allen PJ; Kemeny N
    Ann Surg Oncol; 2009 Jul; 16(7):1844-51. PubMed ID: 19224284
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.